Cancer Genetics and Epigenetics 2024, Vol.12, No.4, 194-209 http://medscipublisher.com/index.php/cge 202 Receiver operating characteristic (ROC) curves and area under the curve (AUC) analyses are commonly used tools to assess the overall performance of the biomarker. These analyses provide a graphical representation of the trade-offs between sensitivity and specificity at different thresholds, helping to determine the biomarker's effectiveness. Multivariate analyses are often employed to adjust for confounding variables and to evaluate the biomarker's independent predictive value. This approach helps isolate the biomarker's true impact, accounting for other factors that might influence the results. When interpreting these statistical results, it is essential to consider the clinical context and the potential implications for patient care. Ensuring that the findings are both statistically significant and clinically relevant is key to translating research into practice. This comprehensive approach ensures that the biomarker can provide meaningful benefits in real-world clinical settings (Tarazona et al., 2019). 6 Case Studies of Clinically Validated Biomarkers 6.1 ctDNA biomarkers: examples and clinical trials Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for colon cancer, providing a non-invasive method to monitor disease status and treatment response. One notable example is the NRG-GI005 (COBRA) trial, which evaluates ctDNA as a predictive biomarker in patients with stage II colon cancer. The trial involves 1,408 patients who, after resection, are randomized to standard care or ctDNA testing with subsequent adjuvant chemotherapy based on ctDNA status. This trial aims to demonstrate that ctDNA can identify patients who benefit from adjuvant chemotherapy, potentially outperforming traditional clinical and pathological features (Morris et al., 2020). Another significant study involves the use of targeted next-generation sequencing (NGS) to track minimal residual disease (MRD) in localized colon cancer. This study enrolled 150 patients and found that ctDNA detection after surgery was associated with poorer disease-free survival, highlighting its potential as an independent predictor of recurrence. Tracking multiple variants in plasma improved MRD detection accuracy to 87.5%, underscoring the utility of ctDNA in postoperative monitoring (Tarazona et al., 2019). In the neoadjuvant setting, a study assessed ctDNA in stage III colon cancer patients receiving chemotherapy before surgery. Results indicated that baseline ctDNA levels were an independent prognostic factor for disease-free survival. This finding supports the use of ctDNA as a biomarker for monitoring treatment response and predicting long-term outcomes in early-stage colon cancer. 6.2 CTCs as diagnostic and prognostic tools Circulating tumor cells (CTCs) are cancer cells that detach from the primary tumor and enter the bloodstream. They serve as valuable biomarkers for diagnosing and monitoring colon cancer due to their direct link to tumor dynamics. CTCs provide real-time insights into the metastatic potential of the cancer, helping predict disease progression and treatment response. For instance, studies have demonstrated that high CTC counts correlate with poor prognosis and increased risk of recurrence in colon cancer patients. In a clinical trial involving metastatic colorectal cancer, CTC enumeration was used to guide treatment decisions. Patients with higher baseline CTC counts were more likely to benefit from aggressive chemotherapy regimens, while those with low or undetectable CTC levels could be spared from unnecessary treatments. This approach helps tailor therapies to individual patient profiles, potentially improving outcomes and reducing treatment-related toxicity (Chen et al., 2020). Moreover, advanced technologies like microfluidic devices and immunomagnetic separation have enhanced CTC detection and characterization. These methods allow for the isolation and analysis of specific subpopulations of CTCs, providing detailed information on tumor heterogeneity and drug resistance mechanisms. Ongoing research aims to integrate CTC analysis with other biomarkers, such as ctDNA and imaging techniques, to create comprehensive diagnostic and monitoring strategies for colon cancer (Zhang et al., 2022). 6.3 Exosomal miRNAs in colon cancer detection Exosomes are small vesicles secreted by cells that contain proteins, lipids, and nucleic acids, including microRNAs (miRNAs). These vesicles play crucial roles in cell communication and can influence various
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==